Expression of p16INK4a and MIB-1 in relation to histopathology and HPV types in cervical adenocarcinoma

International Journal of Oncology

Volumn 32, Issue 2, 2008, Pages 333-340

  Muller, Susanne ^a   Flores Staino, Carmen ^a   Skyldberg, Barbro ^a   Hellström, Ann Cathrin ^a   Johansson, Bo ^a   Hagmar, Bjorn ^b   Wallin, Keng Ling ^a   Andersson, Sonia ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Cervical adenocarcinoma; Human papillomavirus; MIB 1; p16INK4a antigen

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; KI 67 ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CELL PROLIFERATION; CONDYLOMA; CONTROLLED STUDY; CORRELATION FUNCTION; DIAGNOSTIC VALUE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; UTERINE CERVIX CARCINOMA; UTERUS SURGERY; VIRUS TYPING; WART VIRUS; ADENOCARCINOMA; BIOSYNTHESIS; DISEASE COURSE; GENE EXPRESSION REGULATION; METABOLISM; MIDDLE AGED; PAPILLOMA VIRUS; UTERINE CERVIX TUMOR; VIROLOGY; VIRUS INFECTION;

ADENOCARCINOMA; ADULT; AGED; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE EXPRESSION REGULATION, VIRAL; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 38849201730     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.32.2.333     Document Type: Article

References (51)

1. Parkin DM, Pisani P and Ferlay J: Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 80: 827-841, 1999.
2. Vizcaino AP, Moreno V, Bosch FX, et al: International trends in incidence of cervical cancer: II. Squamous-cell carcinoma. Int J Cancer 86: 429-435, 2000.
3. Bergstrom R, Sparen P and Adami HO: Trends in cancer of the cervix uteri in Sweden following cytological screening. Br J Cancer 81: 159-166, 1999.
4. Sasieni P and Adams J: Changing rates of adenocarcinoma and adenosquamous carcinoma of the cervix in England. Lancet 357: 1490-1493, 2001.
5. Smith HO, Tiffany MF, Qualls CR and Key CR: The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States - a 24-year population based study. Gynecol Oncol 78: 97-105, 2000.
6. Zur Hausen H: Human papillomaviruses in the pathogenesis of anogenital cancer. Virology 184: 9-13, 1991.
7. Walboomers JM, Jacobs MV, Manos MM, et al: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189: 12-19, 1999.
8. Zur Hausen H: Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2: 342-350, 2002.
9. Bosch FX, Manos MM, Munoz N, et al: Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 87: 796-802, 1995.
10. Munoz N: Human papillomavirus and cancer: the epidemiological evidence. J Clin Virol 19: 1-5, 2000.
11. Andersson S, Rylander E, Larsson B, Strand A, Silfversvard C and Wilander E: The role of human papillomavirus in cervical adenocarcinoma carcinogenesis. Eur J Cancer 37: 246-250, 2001.
12. Skyldberg BM, Murray E, Lambkin H, Kelehan P and Auer GU: Adenocarcinoma of the uterine cervix in Ireland and Sweden: human papillomavirus infection and biologic alterations. Mod Pathol 12: 675-682, 1999.
13. Andersson S, Rylander E, Larson B, et al: Types of human papillomavirus revealed in cervical adenocarcinomas after DNA sequencing. Oncol Rep 10: 175-179, 2003.
14. Tenti P, Romagnoli S, Silini E, et al: Human papillomavirus types 16 and 18 infection in infiltrating adenocarcinoma of the cervix: PCR analysis of 138 cases and correlation with histologic type and grade. Am J Clin Pathol 106: 52-56, 1996.
15. Khleif SN, DeGregori J, Yee CL, et al: Inhibition of cyclin D-CDK4/ CDK6 activity is associated with ah E2F-mediated induction of cyclin kinase inhibitor activity. Proc Natl Acad Sci USA 93: 4350-4354, 1996.
16. Dray M, Russell P, Dalrymple C, et al: p16(INK4a) as a complementary marker of high-grade intraepithelial lesions of the uterine cervix. I: Experience with squamous lesions in 189 consecutive cervical biopsies. Pathology 37: 112-124, 2005.
17. Masumoto N, Fujii T, Ishikawa M, et al: P16 overexpression and human papillomavirus infection in small cell carcinoma of the uterine cervix. Hum Pathol 34: 778-783, 2003.
18. Agoff SN, Lin P, Morihara J, Mao C, Kiviat NB and Koutsky LA: p16(INK4a) expression correlates with degree of cervical neoplasia: a comparison with Ki-67 expression and detection of high-risk HPV types. Mod Pathol 16: 665-673, 2003.
19. Keating JT, Cviko A, Riethdorf S, et al: Ki-67, cyclin E and p16INK4 are complimentary surrogate biomarkers for human papilloma virus-related cervical neoplasia. Am J Surg Pathol 25: 884-891, 2001.
20. Klaes R, Friedrich T, Spitkovsky D, et al: Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer 92: 276-284, 2001.
21. Klaes R, Benner A, Friedrich T, et al: p16INK4a immunohistochemistry improves interobserver agreement in the diagnosis of cervical intraepithelial neoplasia. Am J Surg Pathol 26: 1389-1399, 2002.
22. Missaoui N, Hmissa S, Frappart L, et al: p16INK4A over-expression and HPV infection in uterine cervix adenocarcinoma. Virchows Arch 448: 597-603, 2006.
23. Lin ZH, Shen XH, Jin Z, et al: Human papillomavirus genotyping by oligonucleotide microarray and p16 expression in uterine cervical intraepithelial neoplasm and in invasive carcinoma in Korean women. Pathol Int 55: 491-496, 2005.
24. Baak JP and Kruse AJ: Use of biomarkers in the evaluation of CIN grade and progression of early CIN. Methods Mol Med 119: 85-99, 2005.
25. Mittal K, Mesia A and Demopoulos RI: MIB-1 expression is useful in distinguishing dysplasia from atrophy in elderly women. Int J Gynecol Pathol 18: 122-124, 1999.
26. Heatley MK: What is the value of proliferation markers in the normal and neoplastic cervix? Histol Histopathol 13: 249-254, 1998.
27. Kruse AJ, Baak JP, Janssen EA, et al: Low- and high-risk CIN 1 and 2 lesions: prospective predictive value of grade, HPV and Ki-67 immuno-quantitative variables. J Pathol 199: 462-470, 2003.
28. Andersson S, Larson B, Hjerpe A, et al: Adenocarcinoma of the uterine cervix: the presence of human papillomavirus and the method of detection. Acta Obstet Gynecol Scand 82: 960-965, 2003.
29. Wang JL, Zheng BY, Li XD, Angstrom T, Lindstrom MS and Wallin KL: Predictive significance of the alterations of p16INK4A, p14ARF, p53 and proliferating cell nuclear antigen expression in the progression of cervical cancer. Clin Cancer Res 10: 2407-2414, 2004.
30. Sano T, Oyama T, Kashiwabara K, Fukuda T and Nakajima T: Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions. Am J Pathol 153: 1741-1748, 1998.
31. Klussmann JP, Gultekin E, Weissenborn SJ, et al: Expression of p16 protein identifies a distinct entity of tonsillar carcinomas associated with human papillomavirus. Am J Pathol 162: 747-753, 2003.
32. Krane JF, Granter SR, Trask CE, Hogan CL and Lee KR: Papanicolaou smear sensitivity for the detection of adenocarcinoma of the cervix: a study of 49 cases. Cancer 93: 8-15, 2001.
33. Saqi A, Pasha TL, McGrath CM, Yu GH, Zhang P and Gupta P: Overexpression of p16INK4A in liquid-based specimens (SurePath) as marker of cervical dysplasia and neoplasia. Diagn Cytopathol 27: 365-370, 2002.
34. Murphy N, Heffron CC, King B, et al: p16INK4A positivity in benign, premalignant and malignant cervical glandular lesions: a potential diagnostic problem. Virchows Arch 445: 610-615, 2004.
35. Nielsen GP, Stemmer-Rachamimov AO, Shaw J, Roy JE, Koh J and Louis DN: Immunohistochemical survey of p16INK4A expression in normal human adult and infant tissues. Lab Invest 79: 1137-1143, 1999.
36. Andersson S, Wangsa D, Flores-Staino C, et al: Expression of p16(INK4a) in relation to histopathology and viral load of 'high-risk' HPV types in cervical neoplastic lesions. Eur J Cancer 42: 2815-2820, 2006.
37. Branca M, Ciotti M, Santini D, et al: p16(INK4A) expression is related to grade of cin and high-risk human papillomavirus but does not predict virus clearance after conization or disease outcome. Int J Gynecol Pathol 23: 354-365, 2004.
38. Negri G, Vittadello F, Romano F, et al: p16INK4a expression and progression risk of low-grade intraepithelial neoplasia of the cervix uteri. Virchows Arch 445: 616-620, 2004.
39. Lee CT, Capodieci P, Osman I, et al: Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer. Clin Cancer Res 5: 977-983, 1999.
40. Ishikawa M, Fujii T, Masumoto N, et al: Correlation of p16INK4A overexpression with human papillomavirus infection in cervical adenocarcinomas. Int J Gynecol Pathol 22: 378-385, 2003.
41. Alfsen GC, Reed W, Sandstad B, Kristensen GB and Abeler VM: The prognostic impact of cyclin dependent kinase inhibitors p21WAF1, p27Kipl and p16INK4/MTS1 in adenocarcinomas of the uterine cervix: an immunohistochemical evaluation of expression patterns in population-based material from 142 patients with international federation of gynecology and obstetrics stage I and II adenocarcinoma. Cancer 98: 1880-1889, 2003.
42. Van de Putte G, Holm R, Lie AK, Trope CG and Kristensen GB: Expression of p27, p21 and p16 protein in early squamous cervical cancer and its relation to prognosis. Gynecol Oncol 89: 140-147, 2003.
43. Sahebali S, Depuydt CE, Segers K, Vereecken AJ, Van Marck E and Bogers JJ: Ki-67 immunocytochemistry in liquid based cervical cytology: useful as an adjunctive tool? J Clin Pathol 56: 681-686, 2003.
44. Lorenzato M, Caudroy S, Bronner C, et al: Cell cycle and/or proliferation markers: what is the best method to discriminate cervical high-grade lesions? Hum Pathol 36: 1101-1107, 2005.
45. Cameron RI, Maxwell P, Jenkins D and McCluggage WG: Immunohistochemical staining with MIB1, bcl2 and p16 assists in the distinction of cervical glandular intraepithelial neoplasia from tubo-endometrial metaplasia, endometriosis and microglandular hyperplasia. Histopathology 41: 313-321, 2002.
46. Cina SJ, Richardson MS, Austin RM and Kurman RJ: Immunohistochemical staining for Ki-67 antigen, carcinoembryonic antigen and p53 in the differential diagnosis of glandular lesions of the cervix. Mod Pathol 10: 176-180, 1997.
47. Barnes W, Delgado G, Kurman RJ, et al: Possible prognostic significance of human papillomavirus type in cervical cancer. Gynecol Oncol 29: 267-273, 1988.
48. Syrjanen KJ: Spontaneous evolution of intraepithelial lesions according to the grade and type of the implicated human papillomavirus (HPV). Eur J Obstet Gynecol Reprod Biol 65: 45-53, 1996.
49. Ho DM, Hsu CY and Chiang H: MIB-1 labeling index as a prognostic indicator for survival in patients with FIGO stage IB squamous cell carcinoma of the cervix. Gynecol Oncol 76: 97-102, 2000.
50. Avall-Lundqvist EH, Silfversward C, Aspenblad U, Nilsson BR and Auer GU: The impact of tumour angiogenesis, p53 over-expression and proliferative activity (MIB-1) on survival in squamous cervical carcinoma. Eur J Cancer 33: 1799-1804, 1997.
51. Graflund M, Sorbe B and Karlsson M: MIB-1, p53, bcl-2 and WAF-1 expression in pelvic lymph nodes and primary tumors in early stage cervical carcinomas: correlation with clinical outcome. Int J Oncol 20: 1041-1047, 2002.